Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
08 Mar 2024
08 Mar 2024
Historique:
received:
07
11
2023
accepted:
28
02
2024
revised:
27
02
2024
medline:
9
3
2024
pubmed:
9
3
2024
entrez:
8
3
2024
Statut:
aheadofprint
Résumé
Axicabtagene ciloleucel showed efficacy for relapsed/refractory large B-cell lymphomas (LBCL), including primary mediastinal B-cell lymphomas (PMBCL); however, only few PMBCLs were reported. Aim was to evaluate efficacy and safety of axicabtagene ciloleucel in patients with PMBCL compared to those with other LBCL, enrolled in the Italian prospective observational CART-SIE study. PMBCLs (n = 70) were younger, with higher percentage of bulky and refractory disease, compared to other LBCLs (n = 190). Median follow-up time for infused patients was 12.17 months (IQR 5.53,22.73). The overall (complete + partial) response rate (ORR,CR + PR) after bridging was 41% for PMBCL and 28% for other LBCL, p = 0.0102. Thirty days ORR was 78% (53/68) with 50% (34) CR in PMBCL, and 75% (141/187) with 53% (100) CR in other LBCL, p = 0.5457. Ninety days ORR was 69% (45/65) with 65% (42) CR in PMBCL, and 54% (87/162) with 47% (76) CR in other LBCL; progressive disease was 21% in PMBCL and 45% in other LBCL, p = 0.0336. Twelve months progression-free survival was 62% (95% CI: 51-75) in PMBCL versus 48% (95% CI: 41-57) in other LBCL, p = 0.0386. Twelve months overall survival was 86% (95% CI: 78-95) in PMBCL versus 71% (95% CI: 64-79) in other LBCL, p = 0.0034. All grade cytokine release syndrome was 88% (228/260); all grade neurotoxicity was 34% (88/260), with 6% of fatal events in PMBCL. Non-relapse mortality was 3%. In conclusion, PMBCLs achieved significantly better response and survival rates than other LBCLs.
Identifiants
pubmed: 38459167
doi: 10.1038/s41375-024-02213-x
pii: 10.1038/s41375-024-02213-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : #PNC-E3-2022-23683269-PNC-HLS-TA
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : "Ricerca Finalizzata 2019" #RF-2019-12370243
Informations de copyright
© 2024. The Author(s).
Références
Savage KJ. Primary mediastinal large B-cell lymphoma. Blood. 2022;140:955–70.
doi: 10.1182/blood.2020008376
pubmed: 34496020
Vardhana S, Hamlin PA, Yang J, Zelenetz A, Sauter CS, Matasar MJ, et al. Outcomes of relapsed and refractory primary mediastinal (Thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant. 2018;24:2133–8.
doi: 10.1016/j.bbmt.2018.06.009
pubmed: 29909154
pmcid: 7517639
Aoki T, Shimada K, Suzuki R, Izutsu K, Tomita A, Maeda Y, et al. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J. 2015;5:e372.
doi: 10.1038/bcj.2015.101
pubmed: 26636287
pmcid: 4735068
Avivi I, Boumendil A, Finel H, Nagler A, De Sousa AB, Santasusana JMR, et al. Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: longterm outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2018;53:1001–9.
doi: 10.1038/s41409-017-0063-7
pubmed: 29463854
Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118:2659–69.
doi: 10.1182/blood-2011-05-326538
pubmed: 21700770
Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37:3291–9.
doi: 10.1200/JCO.19.01389
pubmed: 31609651
pmcid: 6881098
Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142:141–5.
pubmed: 37130017
pmcid: 10651864
Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 Study. J Clin Oncol. 2019;37:3081–9.
doi: 10.1200/JCO.19.01492
pubmed: 31398081
pmcid: 6864847
Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, et al. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up. Blood Adv. 2023;7:5272–80.
doi: 10.1182/bloodadvances.2023010254
pubmed: 37352266
pmcid: 10500465
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8.
doi: 10.1182/blood-2017-03-769620
pubmed: 28774879
pmcid: 5649550
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.
doi: 10.1056/NEJMoa1707447
pubmed: 29226797
pmcid: 5882485
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.
doi: 10.1056/NEJMoa1804980
pubmed: 30501490
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52.
doi: 10.1016/S0140-6736(20)31366-0
pubmed: 32888407
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single arm, multicenter, phase 1-2 trial. Lancet Oncol. 2019;20:31–42.
doi: 10.1016/S1470-2045(18)30864-7
pubmed: 30518502
Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel. Blood. 2023;141:2307–15.
pubmed: 36821768
pmcid: 10646788
Crombie JL, Nastoupil LJ, Redd R, Tang K, Shouse G, Herrera AF, et al. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv. 2021;5:3563–7.
pubmed: 34474474
pmcid: 8945592
Shubert ML, Bethge WA, Ayuk FA, Von Bonin M, Vucinic V, Wagner-Drouet EM, et al. Outcomes of axicabtagene ciloleucel in PMBCL compare favorably to DLBCL: a GLA/DRST registry study. Blood Adv. 2023;7:6191–5.
doi: 10.1182/bloodadvances.2023011203
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.
doi: 10.1200/JCO.2013.54.8800
pubmed: 25113753
pmcid: 4979083
Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in time. Stat Med. 2007;26:4505–19.
doi: 10.1002/sim.2864
pubmed: 17348080
Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–54.
doi: 10.1214/aos/1176350951
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Tranplant. 2019;25:625–38.
doi: 10.1016/j.bbmt.2018.12.758
Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE—version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 2021;112:90–2.
doi: 10.1016/j.ad.2019.05.009
pubmed: 32891586
Freeman GH, Halton JH. Note on exact treatment of contingency, goodness of fit and other problems of significance. Biometrika. 1951;38:141–9.
doi: 10.1093/biomet/38.1-2.141
pubmed: 14848119
Farina A, Birzu C, Elsensohn MH, Picca A, Muniz-Castrillo S, Vogrig A, et al. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun. 2023;5:fcad169.
doi: 10.1093/braincomms/fcad169
pubmed: 37389303
pmcid: 10306160
Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, Von Tresckow B, et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140:349–58.
pubmed: 35316325
Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023;7:2872–83.
doi: 10.1182/bloodadvances.2022009019
pubmed: 36724512
pmcid: 10300297
Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220–31.
doi: 10.1056/NEJMoa2206913
pubmed: 36507690
Liu X, Zhao J, Guo X, Song Y. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting. J Hematol Oncol. 2023;16:90.
doi: 10.1186/s13045-023-01488-4
pubmed: 37537626
pmcid: 10401875
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640–54.
doi: 10.1056/NEJMoa2116133
pubmed: 34891224
Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141:1675–84.
doi: 10.1182/blood.2022018730
pubmed: 36542826